about
T-cell clonotypes in cancerThe melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responsesHAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptidesRhoH is important for positive thymocyte selection and T-cell receptor signalingNatural CD4+ T-cell responses against indoleamine 2,3-dioxygenaseAberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4 + T- Cells, Which Dampen CD8 + T-cell Antitumor ReactivityData analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.Cytotoxic T cells.Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly.Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRsParallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.Broadening the repertoire of melanoma-associated T-cell epitopes.Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes.Defining the critical hurdles in cancer immunotherapy.TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.Regulators of apoptosis: suitable targets for immune therapy of cancer.(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell TransplantationSurvivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanomaAdoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.The universal character of the tumor-associated antigen survivin.The immunogenicity of the hTERT540-548 peptide in cancer.Cancer treatment: the combination of vaccination with other therapies.Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters.Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.Therapeutic cancer vaccines in combination with conventional therapy.The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.Immunotherapy for metastatic colorectal cancer: present status and new options.Immune-suppressive properties of the tumor microenvironment.Self-reactive T cells: suppressing the suppressors.Immunogenicity of Bcl-2 in patients with cancer.Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.Exercise and cancer: from "healthy" to "therapeutic"?
P50
Q24803891-E5160727-1609-41FF-B6ED-48032A7AD5FBQ28249285-FFB88A34-6E17-4BFD-84E6-9DA10C9AE574Q28301267-647BF98D-0F22-4DC3-8E46-5454F24F496CQ28506790-B635C0DF-6F80-497E-9C07-49AA61303955Q28730430-90CD7B45-DCAA-4261-9125-5C6DA25BC391Q30040092-1AA84C61-B95A-4C47-A028-D15059954D04Q30927297-85D88E80-614F-4400-A3B6-FDA616750B90Q33501195-4FDBFBB1-37A9-4615-9BDF-D645FDD60CE5Q34485256-CAA06247-8CFA-4D74-8234-1E49F1FAEF8CQ34491109-FD0ED86C-9673-40D8-9C2F-712137DFFF5AQ34508082-3E39C33B-3264-443B-AADD-10195FB29555Q34707334-BE6F951E-3115-44CA-B0F3-670FF9676B22Q34756907-6B5F371A-9AF0-4CB0-8A08-79BAB8CCA84CQ34988072-D4CEE3B3-FBA3-4F33-8ADD-D7104E725D9DQ35546276-EB2E0CF6-3157-48D7-AA45-D85BE0D97BFEQ35682727-1E763E8B-EE8B-4D5D-B6FB-2D5A4C0D13FBQ35692171-05CB10E1-F054-43DB-A438-371CE9216D26Q35916968-0ABF1CC7-2EA0-4088-BE78-2BCFCBE7E73DQ36057454-9AF4F991-2AC9-4106-81CC-03B3A5D5E7BAQ36111911-62B05E2F-98F8-4468-A811-D8E516C977C6Q36229571-8BBD5E43-AFF1-4E4B-A0DA-88B3DEDE9EB0Q36384933-4A23044A-A905-4C4A-A765-7E1E746809FBQ36444798-45C144A3-1AC7-4EC3-9E35-F4240378B364Q36975578-9E41B219-92E9-4854-81ED-6B15B0E2558DQ37048961-5598EA08-3FDE-41C1-A930-65AC597A68EBQ37089001-F7F40C0C-4DC7-4636-84DD-08F5A61CC841Q37249394-16BD5511-236B-452B-A75D-C6147A67C8C7Q37458758-E91F31D0-84E8-40B4-8A87-671D80B942A3Q37574649-2B6A1F63-A691-432A-A9DD-997AA8BDDC0AQ37771267-B39352DE-D018-4DCD-BFB4-3C5A5D8B10D3Q37838167-BDAA7A47-244E-42C9-853D-CB9AF04BA38BQ37972934-D053F5E1-8A69-46CD-8955-99ABA229BD60Q38105970-9E0B06DA-912A-4E41-BC90-558D5E3C5599Q38173811-ADADF91A-88EB-4C10-9BA6-244F2047B684Q38336726-DD92FF98-6227-41C3-B418-28A9C40A2D30Q38394457-EA67FB6C-99F3-4AE8-9D85-EFFDFD5CE629Q38665896-A4AAF19D-7CB4-48A4-9CC0-2E5566F28140Q38792580-37B508AE-841E-4A54-8A92-AD8276A390C1Q38871209-337C2563-973B-4883-91DB-31DC48C94200Q39190492-7D41BC19-A482-4FF7-B894-F86E9D420207
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Per thor Straten
@ast
Per thor Straten
@en
Per thor Straten
@es
Per thor Straten
@nl
Per thor Straten
@sl
type
label
Per thor Straten
@ast
Per thor Straten
@en
Per thor Straten
@es
Per thor Straten
@nl
Per thor Straten
@sl
prefLabel
Per thor Straten
@ast
Per thor Straten
@en
Per thor Straten
@es
Per thor Straten
@nl
Per thor Straten
@sl
P106
P21
P31
P496
0000-0002-4731-4969